Annual CFI
$14.49 M
+$29.61 M+195.84%
31 December 2023
Summary:
Regulus Therapeutics annual cash flow from investing activities is currently $14.49 million, with the most recent change of +$29.61 million (+195.84%) on 31 December 2023. During the last 3 years, it has risen by +$14.50 million (+131836.36%). RGLS annual CFI is now -68.85% below its all-time high of $46.52 million, reached on 31 December 2018.RGLS Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$18.64 M
+$18.73 M+22562.65%
30 September 2024
Summary:
Regulus Therapeutics quarterly cash flow from investing activities is currently $18.64 million, with the most recent change of +$18.73 million (+22562.65%) on 30 September 2024. Over the past year, it has increased by +$24.08 million (+442.72%). RGLS quarterly CFI is now at all-time high.RGLS Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$55.05 M
+$24.08 M+30.43%
30 September 2024
Summary:
Regulus Therapeutics TTM cash flow from investing activities is currently -$55.05 million, with the most recent change of +$24.08 million (+30.43%) on 30 September 2024. Over the past year, it has dropped by -$75.08 million (-374.90%). RGLS TTM CFI is now -206.57% below its all-time high of $51.66 million, reached on 30 June 2017.RGLS TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RGLS Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +195.8% | +442.7% | -374.9% |
| 3 y3 years | +10000.0% | +10000.0% | -10000.0% |
| 5 y5 years | -68.8% | +10000.0% | -937.5% |
RGLS Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +195.8% | at high | +123.7% | -374.9% | +30.4% |
| 5 y | 5 years | -68.8% | +195.8% | at high | +123.7% | -374.9% | +30.4% |
| alltime | all time | -68.8% | +135.4% | at high | +123.7% | -206.6% | +30.6% |
Regulus Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $18.64 M(<-9900.0%) | -$55.05 M(-30.4%) |
| June 2024 | - | -$83.00 K(-99.9%) | -$79.14 M(+0.1%) |
| Mar 2024 | - | -$78.54 M(-1692.5%) | -$79.05 M(-645.5%) |
| Dec 2023 | $14.49 M(-195.8%) | $4.93 M(-190.7%) | $14.49 M(-27.6%) |
| Sept 2023 | - | -$5.44 M(<-9900.0%) | $20.03 M(+58.9%) |
| June 2023 | - | $0.00(-100.0%) | $12.61 M(<-9900.0%) |
| Mar 2023 | - | $15.00 M(+43.3%) | -$19.00 K(-99.9%) |
| Dec 2022 | -$15.12 M(+5923.9%) | $10.47 M(-181.4%) | -$15.12 M(-41.0%) |
| Sept 2022 | - | -$12.86 M(+1.9%) | -$25.63 M(+100.3%) |
| June 2022 | - | -$12.62 M(>+9900.0%) | -$12.79 M(+4164.3%) |
| Mar 2022 | - | -$102.00 K(+148.8%) | -$300.00 K(+19.5%) |
| Dec 2021 | -$251.00 K(+2181.8%) | -$41.00 K(+57.7%) | -$251.00 K(+19.5%) |
| Sept 2021 | - | -$26.00 K(-80.2%) | -$210.00 K(+7.7%) |
| June 2021 | - | -$131.00 K(+147.2%) | -$195.00 K(+204.7%) |
| Mar 2021 | - | -$53.00 K(<-9900.0%) | -$64.00 K(+481.8%) |
| Dec 2020 | -$11.00 K(-114.9%) | $0.00(-100.0%) | -$11.00 K(-84.3%) |
| Sept 2020 | - | -$11.00 K(<-9900.0%) | -$70.00 K(-65.0%) |
| June 2020 | - | $0.00(0.0%) | -$200.00 K(+129.9%) |
| Mar 2020 | - | $0.00(-100.0%) | -$87.00 K(-217.6%) |
| Dec 2019 | $74.00 K(-99.8%) | -$59.00 K(-58.2%) | $74.00 K(-98.9%) |
| Sept 2019 | - | -$141.00 K(-224.8%) | $6.57 M(-66.5%) |
| June 2019 | - | $113.00 K(-29.8%) | $19.64 M(-44.3%) |
| Mar 2019 | - | $161.00 K(-97.5%) | $35.24 M(-24.2%) |
| Dec 2018 | $46.52 M | $6.44 M(-50.2%) | $46.52 M(+4.6%) |
| Sept 2018 | - | $12.93 M(-17.7%) | $44.48 M(+473.8%) |
| June 2018 | - | $15.71 M(+37.4%) | $7.75 M(+10.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $11.44 M(+160.1%) | $7.01 M(-49.7%) |
| Dec 2017 | $13.94 M(-60.5%) | $4.40 M(-118.5%) | $13.94 M(-44.1%) |
| Sept 2017 | - | -$23.80 M(-258.9%) | $24.92 M(-51.8%) |
| June 2017 | - | $14.98 M(-18.4%) | $51.66 M(+23.0%) |
| Mar 2017 | - | $18.36 M(+19.3%) | $41.98 M(+18.9%) |
| Dec 2016 | $35.31 M(+64.4%) | $15.38 M(+424.0%) | $35.31 M(+7.1%) |
| Sept 2016 | - | $2.94 M(-44.6%) | $32.97 M(-7.2%) |
| June 2016 | - | $5.30 M(-54.7%) | $35.53 M(-12.4%) |
| Mar 2016 | - | $11.69 M(-10.4%) | $40.56 M(+88.9%) |
| Dec 2015 | $21.48 M(-173.5%) | $13.04 M(+137.2%) | $21.48 M(-170.6%) |
| Sept 2015 | - | $5.50 M(-46.7%) | -$30.41 M(+11.3%) |
| June 2015 | - | $10.32 M(-239.7%) | -$27.33 M(+4.6%) |
| Mar 2015 | - | -$7.39 M(-81.0%) | -$26.11 M(-10.6%) |
| Dec 2014 | -$29.21 M(-28.6%) | -$38.84 M(-552.7%) | -$29.21 M(-993.7%) |
| Sept 2014 | - | $8.58 M(-25.6%) | $3.27 M(-110.0%) |
| June 2014 | - | $11.54 M(-210.1%) | -$32.81 M(-7.9%) |
| Mar 2014 | - | -$10.48 M(+64.7%) | -$35.62 M(-12.9%) |
| Dec 2013 | -$40.89 M(+34.6%) | -$6.37 M(-76.9%) | -$40.89 M(-48.4%) |
| Sept 2013 | - | -$27.50 M(-415.3%) | -$79.26 M(+83.2%) |
| June 2013 | - | $8.72 M(-155.4%) | -$43.25 M(-17.2%) |
| Mar 2013 | - | -$15.75 M(-64.8%) | -$52.26 M(+72.0%) |
| Dec 2012 | -$30.38 M(-1014.1%) | -$44.74 M(-625.6%) | -$30.38 M(-311.7%) |
| Sept 2012 | - | $8.51 M(-3129.2%) | $14.35 M(+145.7%) |
| June 2012 | - | -$281.00 K(-104.6%) | $5.84 M(-4.6%) |
| Mar 2012 | - | $6.12 M | $6.12 M |
| Dec 2011 | $3.32 M(-115.1%) | - | - |
| Dec 2010 | -$21.96 M | - | - |
FAQ
- What is Regulus Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Regulus Therapeutics?
- What is Regulus Therapeutics annual CFI year-on-year change?
- What is Regulus Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Regulus Therapeutics?
- What is Regulus Therapeutics quarterly CFI year-on-year change?
- What is Regulus Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Regulus Therapeutics?
- What is Regulus Therapeutics TTM CFI year-on-year change?
What is Regulus Therapeutics annual cash flow from investing activities?
The current annual CFI of RGLS is $14.49 M
What is the all time high annual CFI for Regulus Therapeutics?
Regulus Therapeutics all-time high annual cash flow from investing activities is $46.52 M
What is Regulus Therapeutics annual CFI year-on-year change?
Over the past year, RGLS annual cash flow from investing activities has changed by +$29.61 M (+195.84%)
What is Regulus Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of RGLS is $18.64 M
What is the all time high quarterly CFI for Regulus Therapeutics?
Regulus Therapeutics all-time high quarterly cash flow from investing activities is $18.64 M
What is Regulus Therapeutics quarterly CFI year-on-year change?
Over the past year, RGLS quarterly cash flow from investing activities has changed by +$24.08 M (+442.72%)
What is Regulus Therapeutics TTM cash flow from investing activities?
The current TTM CFI of RGLS is -$55.05 M
What is the all time high TTM CFI for Regulus Therapeutics?
Regulus Therapeutics all-time high TTM cash flow from investing activities is $51.66 M
What is Regulus Therapeutics TTM CFI year-on-year change?
Over the past year, RGLS TTM cash flow from investing activities has changed by -$75.08 M (-374.90%)